Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAD-2000
- Development stage
- Preclinical
- Lead developer
- Cadrenal Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
CAD-2000 is an orally bioavailable small molecule inhibitor of 12-lipoxygenase (12-LOX) currently under development by Cadrenal Therapeutics. As a next-generation compound within the company's 12-LOX portfolio, it is designed to target inflammatory pathways that contribute to metabolic dysfunction. Preclinical studies have demonstrated that oral administration of CAD-2000 improves glycemic control, preserves pancreatic β-cell function, and reduces the presence of inflammatory cells and pro-inflammatory cytokines in adipose and pancreatic tissues. The drug is being positioned for the treatment of inflammatory conditions, specifically obesity and Type 2 diabetes.
02
Targets
ALOX12 (Arachidonate 12-lipoxygenase, 12S type)
Beyond the preview
Go deeper on CAD-2000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAD-2000.